Enlivex
Moran Fattal is a Principal Scientist & Scientific Coordinator at Enlivex Therapeutics (Nasdaq: ENLV) since May 2023. Prior to this role, Moran served as a Principal Scientist at Enlivex Therapeutics starting in December 2021. Moran also has experience as a Research and Development Scientist at Enlivex Therapeutics from January 2019 to June 2022. Before working at Enlivex Therapeutics, Moran worked as a Research Assistant at GluSense Medical from January 2018 to January 2019. Moran's earlier experience includes being a Research Assistant at Valin Technologies from September 2015 to January 2018, a Research Assistant at Orgenesis Inc. from October 2013 to September 2015, a masters student and researcher at Bar Ilan University from 2010 to December 2012, and the Head of the sensory laboratory - QA at Osem Israel (Nestle group) from February 2009 to October 2009. Moran also worked as a Lab Technician at Ben-Gurion University, Dr. Tekoah's Research Laboratory from October 2007 to May 2008.
Moran Fattal completed a Biomedical Data Analyst program at AEAI - Association of Engineers and Architects in Israel in 2023. They also obtained a Project Manager certification from AEAI in the same year. Prior to that, Moran earned a Master of Science degree in Life Science & Biotechnology from Bar-Ilan University in 2012. Their undergraduate education includes a Bachelor of Science in Biotechnology Engineering from Ben-Gurion University of the Negev, which was obtained between 2003 and 2008.
Previous companies
This person is not in any teams
This person is not in any offices
Enlivex
Enlivex's mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, Enlivex intends to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses.